Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accumulated Expenses (2016 - 2025)

Ptc Therapeutics has reported Accumulated Expenses over the past 12 years, most recently at $73.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $73.7 million for Q4 2025, up 19.75% from a year ago — trailing twelve months through Dec 2025 was $73.7 million (up 19.75% YoY), and the annual figure for FY2025 was $73.7 million, up 19.75%.
  • Accumulated Expenses for Q4 2025 was $73.7 million at Ptc Therapeutics, up from $49.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PTCT hit a ceiling of $73.7 million in Q4 2025 and a floor of $500000.0 in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $36.6 million (2023), compared with a mean of $38.5 million.
  • Biggest five-year swings in Accumulated Expenses: surged 5797.0% in 2022 and later crashed 80.2% in 2024.
  • Ptc Therapeutics' Accumulated Expenses stood at $35.7 million in 2021, then rose by 13.64% to $40.5 million in 2022, then surged by 54.5% to $62.6 million in 2023, then dropped by 1.7% to $61.6 million in 2024, then increased by 19.75% to $73.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $73.7 million (Q4 2025), $49.5 million (Q3 2025), and $38.2 million (Q2 2025) per Business Quant data.